Further evidence for the potential of KRAS-G12C inhibition to reduce the immunosuppressive tumour microenvironment produced by oncogenic KRAS and potentially sensitise tumours to immune checkpoint blockade came from another study using the 3LL ΔNRAS murine lung carcinoma line [118]. This evidence concerns the gene KRAS and lung carcinoma.